In 2023, a group of British government officials, self-styled as the "Rebel Alliance," formed an internal opposition to Palantir Technologies, a US-based software company seeking to secure a major contract with England’s National Health Service (NHS). The company was on the verge of obtaining a seven-year, £330 million deal to supply the NHS with a Federated Data Platform (FDP), which aimed to unify the healthcare system’s diverse technology infrastructure.

Palantir's Foundry software, initially introduced during the early stages of the COVID-19 pandemic, helped manage critical pandemic logistics, including ventilators, personal protective equipment, and vaccines, under a low-cost contract. This early involvement led to a subsequent £23.5 million contract in December 2020 focused on reducing NHS waiting lists. The FDP contract offered Palantir the chance to further embed its technology and personnel within NHS operations, culminating in the high-profile seven-year agreement.

However, the procurement process and the contract itself have drawn scrutiny and criticism. Some government insiders and rival bidders claim the tender was tailored to Palantir's technology and that the bidding process was biased, with features and tender language aligning closely with Palantir’s existing systems. This allegedly discouraged UK-based companies from competing, leaving only two main consortia in the final selection—one led by Palantir and its partners PwC, Accenture, and healthcare consultancies, and the other by IBM and UK data firm Quantexa. NHS England defends the procurement as rigorous, competitive, and compliant with public contract rules.

There has also been debate about the contract’s structure and pricing. Officials raised concerns about relying on a single supplier for such a significant project, diverging from NHS norms of splitting large contracts to foster competition and reduce dependency. While a portion of the contract related to data security was assigned to US health tech company IQVIA, the main contract remained intact despite Cabinet Office resistance. Critics noted that pricing incentivized widespread adoption of the system, with costs counterintuitively higher for fewer hospitals, though explanations for the model were unclear.

Technically, the FDP’s role is to aggregate operational data such as waiting lists, staffing, treatment details, theater schedules, and bed availability into a unified interface. Supporters highlight that the system has helped perform around 110,000 additional operations, cut discharge delays by 15%, and reduce waiting lists by approximately 800,000 patients. Nevertheless, some analysts argue these improvements are localized to a few hospitals, and others observed performance declines after adopting the software. Critics contend the FDP functions more as a database with applications layered on, falling short of claims to fully integrate NHS data or improve care comprehensively.

The contract’s geopolitical implications have attracted significant attention. Palantir’s links to the US government and military, including past contracts with Immigration and Customs Enforcement and the Israel Defense Forces, have fueled concerns among UK officials and the public. Several European countries—France, Germany, and Switzerland—have recently limited or severed Palantir contracts in their defense and intelligence sectors amid broader worries over US foreign policy and technology sovereignty. In London, the mayor’s office blocked a £50 million contract for Palantir with the capital’s police force, citing ethical considerations.

Palantir’s UK chief executive, Louis Mosley, rejects claims that the company is politically motivated, describing Palantir as ideological in its support for liberal democracy and the rule of law. He emphasizes that UK NHS data remains hosted on British soil and that the company’s Foundry platform was developed in the UK. Mosley argues there are no technical barriers preventing the NHS from switching to alternative systems if superior options emerge.

Critics, however, including academics and industry insiders, stress the importance of nurturing domestic technology innovation. They argue that awarding such a large public contract to a foreign firm has stifled British digital development and weakened the local tech sector. Some former government affiliates highlight how UK AI companies like Faculty have ceased NHS work, signaling challenges for homegrown firms.

Looking ahead, the UK government has indicated a shift toward prioritizing British companies in future technology procurements. Science Minister Lord Patrick Vallance has advocated for a “very different way of doing contracts,” emphasizing innovation rooted in the UK. Meanwhile, political and public pressures are mounting to reconsider or potentially terminate Palantir’s NHS contract when the break clause becomes available in 2027. Government ministers are reportedly exploring the technical feasibility of removing Palantir systems from NHS infrastructure.

For its part, Palantir is preparing to defend its position, stressing the value its software brings to public service improvements. Mosley acknowledges the political challenges but remains resolute: “Our plan is to grow and — because of what our software does — meaningfully improve public services as we do that.”